TY - JOUR AU - Richon, V. M. PY - 2006 DA - 2006// TI - Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilidehydroxamic acid), a novel histone deacetylase inhibitor JO - Br J Cancer. VL - 95 UR - https://doi.org/10.1038/sj.bjc.6603463 DO - 10.1038/sj.bjc.6603463 ID - Richon2006 ER - TY - JOUR AU - Takada, Y. AU - Gillenwater, A. AU - Ichikawa, H. AU - Aggarwal, B. B. PY - 2006 DA - 2006// TI - Suberoylanilidehydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation JO - J Biol Chem VL - 281 UR - https://doi.org/10.1074/jbc.M507213200 DO - 10.1074/jbc.M507213200 ID - Takada2006 ER - TY - STD TI - Doi T, Hamaguchi T, Shirao K, Chin K, Hatake K, Noguchi K, et al. Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. Int J Clin Oncol. 2013;18:87–95. ID - ref3 ER - TY - JOUR AU - Claerhout, S. AU - Lim, J. Y. AU - Choi, W. AU - Park, Y. Y. AU - Kim, K. AU - Kim, S. B. PY - 2011 DA - 2011// TI - Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer JO - PLoS One VL - 6 UR - https://doi.org/10.1371/journal.pone.0024662 DO - 10.1371/journal.pone.0024662 ID - Claerhout2011 ER - TY - JOUR AU - Jin, J. S. AU - Tsao, T. Y. AU - Sun, P. C. AU - Yu, C. P. AU - Tzao, C. PY - 2012 DA - 2012// TI - SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin JO - Pathol Oncol Res. VL - 18 UR - https://doi.org/10.1007/s12253-012-9499-7 DO - 10.1007/s12253-012-9499-7 ID - Jin2012 ER - TY - JOUR AU - Chinnaiyan, P. AU - Chowdhary, S. AU - Potthast, L. AU - Prabhu, A. AU - Tsai, Y. Y. AU - Sarcar, B. PY - 2012 DA - 2012// TI - Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma JO - Neuro Oncol. VL - 14 UR - https://doi.org/10.1093/neuonc/nor187 DO - 10.1093/neuonc/nor187 ID - Chinnaiyan2012 ER - TY - JOUR AU - Ramaswamy, B. AU - Fiskus, W. AU - Cohen, B. AU - Pellegrino, C. AU - Hershman, D. L. AU - Chuang, E. PY - 2012 DA - 2012// TI - Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo JO - Breast Cancer Res Treat VL - 132 UR - https://doi.org/10.1007/s10549-011-1928-x DO - 10.1007/s10549-011-1928-x ID - Ramaswamy2012 ER - TY - JOUR AU - Liu, Y. L. AU - Yang, P. M. AU - Shun, C. T. AU - Wu, M. S. AU - Weng, J. R. AU - Chen, C. C. PY - 2010 DA - 2010// TI - Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma JO - Autophagy. VL - 6 UR - https://doi.org/10.4161/auto.6.8.13365 DO - 10.4161/auto.6.8.13365 ID - Liu2010 ER - TY - JOUR AU - Kwak, T. W. AU - Kim do, H. AU - Chung, C. W. AU - Lee, H. M. AU - Kim, C. H. AU - Jeong, Y. I. PY - 2013 DA - 2013// TI - Synergistic anticancer effects of vorinostat and epigallocatechin-3-gallate against HuCC-T1 human cholangiocarcinoma cells JO - Evid Based Complement Altern Med. VL - 2013 ID - Kwak2013 ER - TY - JOUR AU - Lim, J. H. PY - 2003 DA - 2003// TI - Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings JO - Am J Roentgenol VL - 181 UR - https://doi.org/10.2214/ajr.181.3.1810819 DO - 10.2214/ajr.181.3.1810819 ID - Lim2003 ER - TY - JOUR AU - Khan, S. A. AU - Taylor-Robinson, S. D. AU - Toledano, M. B. AU - Beck, A. AU - Elliott, P. AU - Thomas, H. C. PY - 2002 DA - 2002// TI - Changing international trends in mortality rates for liver, biliary and pancreatic tumours JO - J Hepatol VL - 37 UR - https://doi.org/10.1016/S0168-8278(02)00297-0 DO - 10.1016/S0168-8278(02)00297-0 ID - Khan2002 ER - TY - JOUR AU - Sirica, A. E. PY - 2005 DA - 2005// TI - Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy JO - Hepatology VL - 41 UR - https://doi.org/10.1002/hep.20537 DO - 10.1002/hep.20537 ID - Sirica2005 ER - TY - JOUR AU - Ciombor, K. K. AU - Goff, L. W. PY - 2013 DA - 2013// TI - Advances in the management of biliary tract cancers JO - Clin Adv Hematol Oncol. VL - 11 ID - Ciombor2013 ER - TY - JOUR AU - Brunner, T. B. AU - Eccles, C. L. PY - 2010 DA - 2010// TI - Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma JO - Strahlenther Onkol VL - 186 UR - https://doi.org/10.1007/s00066-010-2161-y DO - 10.1007/s00066-010-2161-y ID - Brunner2010 ER - TY - JOUR AU - Skipworth, J. R. AU - Olde Damink, S. W. AU - Imber, C. AU - Bridgewater, J. AU - Pereira, S. P. AU - Malagó, M. PY - 2011 DA - 2011// TI - Surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer JO - Aliment Pharmacol Ther. VL - 34 UR - https://doi.org/10.1111/j.1365-2036.2011.04851.x DO - 10.1111/j.1365-2036.2011.04851.x ID - Skipworth2011 ER - TY - JOUR AU - Rizvi, S. AU - Gores, G. J. PY - 2013 DA - 2013// TI - Pathogenesis, diagnosis and management of cholangiocarcinoma JO - Gastroenterology VL - 145 UR - https://doi.org/10.1053/j.gastro.2013.10.013 DO - 10.1053/j.gastro.2013.10.013 ID - Rizvi2013 ER - TY - JOUR AU - Cereda, S. AU - Passoni, P. AU - Reni, M. AU - Viganò, M. G. AU - Aldrighetti, L. AU - Nicoletti, R. PY - 2010 DA - 2010// TI - The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma JO - Cancer VL - 116 ID - Cereda2010 ER - TY - JOUR AU - Kim, S. T. AU - Park, J. O. AU - Lee, J. AU - Lee, K. T. AU - Lee, J. K. AU - Choi, S. H. PY - 2006 DA - 2006// TI - A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer JO - Cancer VL - 106 UR - https://doi.org/10.1002/cncr.21741 DO - 10.1002/cncr.21741 ID - Kim2006 ER - TY - JOUR AU - Valle, J. AU - Wasan, H. AU - Palmer, D. H. AU - Cunningham, D. AU - Anthoney, A. AU - Maraveyas, A. PY - 2010 DA - 2010// TI - Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer JO - N Engl J Med VL - 362 UR - https://doi.org/10.1056/NEJMoa0908721 DO - 10.1056/NEJMoa0908721 ID - Valle2010 ER - TY - JOUR AU - Leong, E. AU - Chen, W. W. AU - Ng, E. AU - Hazel, G. AU - Mitchell, A. AU - Spry, N. PY - 2012 DA - 2012// TI - Outcomes from combined chemoradiotherapy in unresectable and locally advanced resected cholangiocarcinoma JO - J Gastrointest Cancer. VL - 43 UR - https://doi.org/10.1007/s12029-010-9213-5 DO - 10.1007/s12029-010-9213-5 ID - Leong2012 ER - TY - STD TI - Furuse J, Okusaka T. Targeted therapy for biliary tract cancer. Cancers (Basel). 2011;3:2243–54. ID - ref21 ER - TY - JOUR AU - Braga, H. J. AU - Imam, K. AU - Bluemke, D. A. PY - 2011 DA - 2011// TI - MR imaging of intrahepatic cholangiocarcinoma: use of ferumoxides for lesion localization and extension JO - Am J Roentgenol VL - 177 UR - https://doi.org/10.2214/ajr.177.1.1770111 DO - 10.2214/ajr.177.1.1770111 ID - Braga2011 ER - TY - JOUR AU - Lee, Y. AU - Lee, J. S. AU - Kim, C. M. AU - Jeong, J. Y. AU - Choi, J. I. AU - Kim, M. J. PY - 2008 DA - 2008// TI - Area of paradoxical signal drop after the administration of superparamagnetic iron oxide on the T2-weighted image of a patient with lymphangitic metastasis of the liver JO - Magn Reson Imaging VL - 26 UR - https://doi.org/10.1016/j.mri.2007.10.012 DO - 10.1016/j.mri.2007.10.012 ID - Lee2008 ER - TY - JOUR AU - Tang, T. AU - Zheng, J. W. AU - Chen, B. AU - Li, H. AU - Li, X. AU - Xue, K. Y. PY - 2007 DA - 2007// TI - Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice JO - Hepatobiliary Pancreat Dis Int. VL - 6 ID - Tang2007 ER - TY - JOUR AU - Towata, T. AU - Komizu, Y. AU - Kariya, R. AU - Suzu, S. AU - Matsumoto, Y. AU - Kobayashi, N. PY - 2010 DA - 2010// TI - Hybrid liposomes inhibit the growth of cholangiocarcinoma by induction of cell cycle arrest in G1 phase JO - Bioorg Med Chem Lett VL - 20 UR - https://doi.org/10.1016/j.bmcl.2010.04.091 DO - 10.1016/j.bmcl.2010.04.091 ID - Towata2010 ER - TY - JOUR AU - Chung, K. D. AU - Jeong, Y. I. AU - Chung, C. W. AU - Kim do, H. AU - Kang, D. H. PY - 2012 DA - 2012// TI - Anti-tumor activity of all-trans retinoic acid-incorporated glycol chitosan nanoparticles against HuCC-T1 human cholangiocarcinoma cells JO - Int J Pharm VL - 422 UR - https://doi.org/10.1016/j.ijpharm.2011.10.057 DO - 10.1016/j.ijpharm.2011.10.057 ID - Chung2012 ER - TY - JOUR AU - Hwang, J. H. AU - Choi, C. W. AU - Kim do, H. W. AU - Kim, H. AU - Kwak, T. W. AU - Lee, H. M. PY - 2013 DA - 2013// TI - Dextran-b-poly(l-histidine) copolymer nanoparticles for pH-responsive drug delivery to tumor cells JO - Int J Nanomedicine. VL - 8 ID - Hwang2013 ER - TY - JOUR AU - Gref, R. AU - Minamitake, Y. AU - Peracchia, M. T. AU - Trubetskoy, V. AU - Torchilin, V. AU - Langer, R. PY - 1994 DA - 1994// TI - Biodegradable long-circulating polymeric nanospheres JO - Science VL - 263 UR - https://doi.org/10.1126/science.8128245 DO - 10.1126/science.8128245 ID - Gref1994 ER - TY - JOUR AU - Oh, J. K. PY - 2011 DA - 2011// TI - Polylactide (PLA)-based amphiphilic block copolymers: synthesis, self-assembly and biomedical applications JO - Soft Matter VL - 7 UR - https://doi.org/10.1039/c0sm01539c DO - 10.1039/c0sm01539c ID - Oh2011 ER - TY - JOUR AU - Morine, Y. AU - Shimada, M. AU - Iwahashi, S. AU - Utsunomiya, T. AU - Imura, S. AU - Ikemoto, T. PY - 2012 DA - 2012// TI - Role of histone deacetylase expression in intrahepatic cholangiocarcinoma JO - Surgery. VL - 151 UR - https://doi.org/10.1016/j.surg.2011.07.038 DO - 10.1016/j.surg.2011.07.038 ID - Morine2012 ER - TY - JOUR AU - Sun, W. J. AU - Zhou, X. AU - Zheng, J. H. AU - Lu, M. D. AU - Nie, J. Y. AU - Yang, X. J. PY - 2012 DA - 2012// TI - Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis JO - Acta Biochim Biophys Sin (Shanghai) VL - 44 UR - https://doi.org/10.1093/abbs/gmr113 DO - 10.1093/abbs/gmr113 ID - Sun2012 ER - TY - JOUR AU - Boonjaraspinyo, S. AU - Boonmars, T. AU - Kaewkes, S. AU - Laummaunwai, P. AU - Pinlaor, S. AU - Loilome, W. PY - 2012 DA - 2012// TI - Down-regulated expression of HSP70 in correlation with clinicopathology of cholangiocarcinoma JO - Pathol Oncol Res. VL - 18 UR - https://doi.org/10.1007/s12253-011-9432-5 DO - 10.1007/s12253-011-9432-5 ID - Boonjaraspinyo2012 ER - TY - JOUR AU - Weichert, W. AU - Röske, A. AU - Gekeler, V. AU - Beckers, T. AU - Ebert, M. P. AU - Pross, M. PY - 2008 DA - 2008// TI - Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis JO - Lancet Oncol. VL - 9 UR - https://doi.org/10.1016/S1470-2045(08)70004-4 DO - 10.1016/S1470-2045(08)70004-4 ID - Weichert2008 ER - TY - JOUR AU - Weichert, W. PY - 2009 DA - 2009// TI - HDAC expression and clinical prognosis in human malignancies JO - Cancer Lett VL - 280 UR - https://doi.org/10.1016/j.canlet.2008.10.047 DO - 10.1016/j.canlet.2008.10.047 ID - Weichert2009 ER - TY - JOUR AU - Fang, J. Y. PY - 2005 DA - 2005// TI - Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers JO - J Gastroenterol Hepatol VL - 20 UR - https://doi.org/10.1111/j.1440-1746.2005.03807.x DO - 10.1111/j.1440-1746.2005.03807.x ID - Fang2005 ER - TY - JOUR AU - Xu, W. S. AU - Parmigiani, R. B. AU - Marks, P. A. PY - 2007 DA - 2007// TI - Histone deacetylase inhibitors: molecular mechanisms of action JO - Oncogene VL - 26 UR - https://doi.org/10.1038/sj.onc.1210620 DO - 10.1038/sj.onc.1210620 ID - Xu2007 ER - TY - JOUR AU - Vigushin, D. M. AU - Coombes, R. C. PY - 2012 DA - 2012// TI - Histone deacetylase inhibitors in cancer treatment JO - Anticancer Drugs VL - 13 UR - https://doi.org/10.1097/00001813-200201000-00001 DO - 10.1097/00001813-200201000-00001 ID - Vigushin2012 ER - TY - JOUR AU - Yan, W. AU - Liu, S. AU - Xu, E. AU - Zhang, J. AU - Zhang, Y. AU - Chen, X. PY - 2013 DA - 2013// TI - Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8 JO - Oncogene VL - 32 UR - https://doi.org/10.1038/onc.2012.81 DO - 10.1038/onc.2012.81 ID - Yan2013 ER - TY - JOUR AU - Li, D. AU - Marchenko, N. D. AU - Moll, U. M. PY - 2011 DA - 2011// TI - SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis JO - Cell Death Differ VL - 18 UR - https://doi.org/10.1038/cdd.2011.71 DO - 10.1038/cdd.2011.71 ID - Li2011 ER - TY - JOUR AU - Chen, Y. X. AU - Fang, J. Y. AU - Zhu, H. Y. AU - Lu, R. AU - Cheng, Z. H. AU - Qiu, D. K. PY - 2004 DA - 2004// TI - Histone acetylation regulates p21WAF1 expression in human colon cancer cell lines JO - World J Gastroenterol VL - 10 ID - Chen2004 ER - TY - JOUR AU - Said, T. K. AU - Moraes, R. C. B. AU - Sinha, R. AU - Medina, D. PY - 2001 DA - 2001// TI - Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth JO - Breast Cancer Res VL - 3 UR - https://doi.org/10.1186/bcr284 DO - 10.1186/bcr284 ID - Said2001 ER - TY - JOUR AU - Gennaro, E. AU - Piro, G. AU - Chianese, M. I. AU - Franco, R. AU - Cintio, A. AU - Moccia, T. AU - Luciano, A. AU - Ruggiero, I. AU - Bruzzese, F. AU - Avallone, A. AU - Arra, C. AU - Budillon, A. PY - 2010 DA - 2010// TI - Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase JO - Br J Cancer VL - 103 UR - https://doi.org/10.1038/sj.bjc.6605969 DO - 10.1038/sj.bjc.6605969 ID - Gennaro2010 ER - TY - JOUR AU - Wang, E. C. AU - Min, Y. AU - Palm, R. C. AU - Fiordalisi, J. J. AU - Wagner, K. T. AU - Hyder, N. AU - Cox, A. D. AU - Caster, J. M. AU - Tian, X. AU - Wang, A. Z. PY - 2015 DA - 2015// TI - Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors JO - Biomaterials VL - 51 UR - https://doi.org/10.1016/j.biomaterials.2015.02.015 DO - 10.1016/j.biomaterials.2015.02.015 ID - Wang2015 ER - TY - JOUR AU - Li, J. AU - Gong, C. AU - Feng, X. AU - Zhou, X. AU - Xu, X. AU - Xie, L. PY - 2012 DA - 2012// TI - Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0033860 DO - 10.1371/journal.pone.0033860 ID - Li2012 ER - TY - JOUR AU - Mohamed, E. A. AU - Zhao, Y. AU - Meshali, M. M. AU - Remsberg, C. M. AU - Borg, T. M. AU - Foda, A. M. PY - 2012 DA - 2012// TI - Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(dl-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine JO - J Pharm Sci VL - 101 UR - https://doi.org/10.1002/jps.23265 DO - 10.1002/jps.23265 ID - Mohamed2012 ER - TY - JOUR AU - Kim, J. Y. AU - Shim, G. AU - Choi, H. W. AU - Park, J. AU - Chung, S. W. AU - Kim, S. PY - 2012 DA - 2012// TI - Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex JO - Biomaterials VL - 33 UR - https://doi.org/10.1016/j.biomaterials.2012.02.066 DO - 10.1016/j.biomaterials.2012.02.066 ID - Kim2012 ER - TY - JOUR AU - Thomas, M. B. PY - 2014 DA - 2014// TI - Systemic and targeted therapy for biliary tract tumors and primary liver tumors JO - Surg Oncol Clin N Am VL - 23 UR - https://doi.org/10.1016/j.soc.2013.11.004 DO - 10.1016/j.soc.2013.11.004 ID - Thomas2014 ER - TY - JOUR AU - Park, W. AU - Park, S. J. AU - Na, K. PY - 2011 DA - 2011// TI - The controlled photoactivity of nanoparticles derived from ionic interactions between a water soluble polymeric photosensitizer and polysaccharide quencher JO - Biomaterials VL - 32 UR - https://doi.org/10.1016/j.biomaterials.2011.07.023 DO - 10.1016/j.biomaterials.2011.07.023 ID - Park2011 ER - TY - JOUR AU - Maeda, H. AU - Wu, J. AU - Sawa, T. AU - Matsumura, Y. AU - Hori, K. PY - 2000 DA - 2000// TI - Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review JO - J Control Release. VL - 65 UR - https://doi.org/10.1016/S0168-3659(99)00248-5 DO - 10.1016/S0168-3659(99)00248-5 ID - Maeda2000 ER - TY - JOUR AU - Iyer, A. K. AU - Khaled, G. AU - Fang, J. AU - Maeda, H. PY - 2006 DA - 2006// TI - Exploiting the enhanced permeability and retention effect for tumor targeting JO - Drug Discov Today. VL - 11 UR - https://doi.org/10.1016/j.drudis.2006.07.005 DO - 10.1016/j.drudis.2006.07.005 ID - Iyer2006 ER -